Lipocine Inc (LPCN)
NASDAQ:LPCN
Want to see LPCN full AI Analyst Report?
Top Page
Lipocine
(NASDAQ:LPCN)
Select Model
Select Model
Rating:45Neutral
Price Target:
$2.00
▼(-31.51% Downside)
Action:Reiterated
Date:06/13/26
The score is held down primarily by weak financial performance (loss-making with persistent cash burn) and bearish longer-term technicals (price well below 100/200-day averages with negative MACD). Corporate events provide some offset from continued program visibility, but the Phase 3 primary-endpoint miss and uncertain path forward limit the upside; valuation is also not supportive due to losses and no dividend.
Positive Factors
Low leverage / strong balance sheet
Zero reported debt and materially improved equity provide durable financial flexibility to fund near-term development choices, support regulatory interactions, and pursue partnering or strategic alternatives without immediate leverage pressure, reducing refinancing risk over months.
Negative Factors
Negative operating cash flow / cash burn
Sustained negative operating and free cash flow creates ongoing funding dependence. Over a multi-month horizon this elevates dilution or financing risk, constrains the ability to execute development programs internally, and limits optionality absent new capital or partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
Zero reported debt and materially improved equity provide durable financial flexibility to fund near-term development choices, support regulatory interactions, and pursue partnering or strategic alternatives without immediate leverage pressure, reducing refinancing risk over months.
Read all positive factors
Lipocine (LPCN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$18.63M
Dividend YieldN/A
Average Volume (3M)107.70K
Price to Earnings (P/E)―
Beta (1Y)0.52
Revenue Growth-45.52%
EPS Growth-94.82%
CountryUS
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.96
Shares Outstanding8,244,253
10 Day Avg. Volume132,650
30 Day Avg. Volume107,696
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.02
Price to Sales (P/S)22.14
P/FCF Ratio-4.48
Enterprise Value/Market Cap0.43
Enterprise Value/Revenue4.02
Enterprise Value/Gross Profit-48.93
Enterprise Value/Ebitda-0.71
Forecast
1Y Price Target
$6.00Price Target Upside105.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.91
Revenue Forecast (FY)$650.00K
Lipocine Business Overview & Revenue Model
Company Description
Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research ...
How the Company Makes Money
null...
Lipocine Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.00M | 1.98M | 11.20M | -2.85M | 500.00K | 16.14M |
| Gross Profit | -164.35K | -6.61M | 11.20M | -13.03M | -8.06M | 8.48M |
| EBITDA | -11.37M | -9.57M | 50.14K | -16.32M | -10.72M | -430.53K |
| Net Income | -11.43M | -9.63M | 8.35K | -16.35M | -10.76M | -634.40K |
Balance Sheet | ||||||
| Total Assets | 25.36M | 17.01M | 22.51M | 23.00M | 37.54M | 52.48M |
| Cash, Cash Equivalents and Short-Term Investments | 24.73M | 14.93M | 21.63M | 22.04M | 32.53M | 44.62M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.31M |
| Total Liabilities | 2.53M | 2.53M | 1.51M | 2.63M | 1.91M | 6.91M |
| Stockholders Equity | 22.83M | 14.48M | 21.00M | 20.37M | 35.63M | 45.57M |
Cash Flow | ||||||
| Free Cash Flow | -10.05M | -9.76M | -1.31M | -11.88M | -12.10M | -4.42M |
| Operating Cash Flow | -10.05M | -9.76M | -1.22M | -11.87M | -11.97M | -4.41M |
| Investing Cash Flow | -3.13M | 5.89M | 2.45M | 13.08M | 14.29M | -43.78M |
| Financing Cash Flow | 14.84M | 2.87M | 209.34K | 404.57K | -2.13M | 26.92M |
Lipocine Technical Analysis
Neutral
2.92
Price Trends
2.27
Negative
5.45
Negative
4.69
Negative
Market Momentum
-0.17
Negative
45.25
Neutral
50.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LPCN, the sentiment is Neutral. The current price of 2.92 is above the 20-day moving average (MA) of 2.20, above the 50-day MA of 2.27, and below the 200-day MA of 4.69, indicating a neutral trend. The MACD of -0.17 indicates Negative momentum. The RSI at 45.25 is Neutral, neither overbought nor oversold. The STOCH value of 50.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LPCN.
Lipocine Risk Analysis
Lipocine disclosed 61 risk factors in its most recent earnings report. Lipocine reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Lipocine Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $18.63M | -1.34 | -66.69% | ― | -45.52% | -94.82% | |
45 Neutral | $13.10M | -1.22 | -317.47% | ― | -100.00% | 59.83% | |
43 Neutral | $5.11M | -1.13 | -79.47% | ― | -100.00% | 62.88% | |
42 Neutral | $83.96M | -7.32 | -53.86% | ― | -20.00% | 75.26% | |
41 Neutral | $17.45M | -0.09 | -83.59% | ― | ― | 19.36% |
* Healthcare Sector Average
LPCN
Lipocine
2.26
-0.80
-26.14%
IBIO
Ibio
1.69
0.82
93.36%
PULM
Pulmatrix
1.40
-7.30
-83.91%
BCDA
BioCardia
0.88
-1.42
-61.74%
SNSE
Sensei Biotherapeutics
13.00
6.48
99.39%
ASBP
Aspire Biopharma Holdings
4.96
-418.52
-98.83%
Lipocine Corporate Events
Business Operations and StrategyProduct-Related Announcements
Lipocine Advances LPCN 1154 for Postpartum Depression
Positive
Jun 12, 2026
On June 12, 2026, Lipocine hosted a virtual key opinion leader event to highlight the unmet medical needs in postpartum depression and to present the clinical profile of its investigational therapy LPCN 1154. By convening experts to discuss this c...
Executive/Board ChangesShareholder Meetings
Lipocine Shareholders Approve Directors, Auditor and Incentive Plan
Positive
Jun 4, 2026
On June 3, 2026, Lipocine shareholders held their annual general meeting and elected four directors, including Dr. Mahesh V. Patel and three other nominees, to one-year terms, with no abstentions recorded in the director elections. Shareholders al...
Business Operations and StrategyProduct-Related Announcements
Lipocine Plans KOL Webinar on Oral PPD Candidate
Positive
Jun 4, 2026
On June 4, 2026, Lipocine announced it would host a virtual Key Opinion Leader webinar on June 12, 2026, to highlight unmet needs in postpartum depression and discuss the clinical profile of its investigational oral brexanolone candidate, LPCN 115...
Business Operations and StrategyProduct-Related Announcements
Lipocine Showcases Phase 3 Data in Postpartum Depression
Positive
May 26, 2026
On May 26, 2026, Lipocine presented Phase 3 clinical data for LPCN 1154, an oral formulation of brexanolone for the treatment of postpartum depression, at the American Society of Clinical Psychopharmacology Annual Meeting in Miami Beach, Florida. ...
Business Operations and StrategyProduct-Related Announcements
Lipocine Showcases Phase 3 Data for Postpartum Depression
Positive
May 19, 2026
On May 19, 2026, Lipocine announced that Phase 3 clinical data for LPCN 1154, its oral brexanolone candidate for postpartum depression, were accepted for both oral and poster presentations at the 2026 American Society of Clinical Psychopharmacolog...
Business Operations and Strategy
Lipocine Showcases Pipeline at Virtual Healthcare Conference
Positive
May 18, 2026
On May 18, 2026, Lipocine announced that its management would participate in a fireside chat at A.G.P.’s Annual Virtual Healthcare Company Showcase, scheduled for Wednesday, May 20, 2026, at 3:00 p.m. ET. The appearance underscores the compa...
Business Operations and StrategyRegulatory Filings and Compliance
Lipocine Updates Corporate Presentation for Investor Communications
Neutral
May 7, 2026
Lipocine disclosed that it has updated the corporate presentation it uses in meetings with investors, analysts and other stakeholders. The refreshed materials have been formally filed and are intended to guide ongoing discussions with the financia...
Business Operations and StrategyExecutive/Board Changes
Lipocine Reshapes Board Leadership Amid Strategic Shift
Neutral
Apr 21, 2026
On April 16, 2026, Lipocine Inc. announced that Spyros Papapetropoulos resigned from the Board of Directors, effective immediately, stepping down as Chairman, Lead Independent Director, and member of the compensation committee after serving since ...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Lipocine weighs path after LPCN 1154 Phase 3 miss
Negative
Apr 2, 2026
On April 2, 2026, Lipocine reported topline results from a Phase 3 placebo-controlled trial of LPCN 1154, an oral formulation of brexanolone for postpartum depression, in 90 patients. The study did not meet its primary endpoint, as LPCN 1154 faile...
Business Operations and StrategyRegulatory Filings and Compliance
Lipocine Updates Investor Presentation to Refine Market Messaging
Neutral
Apr 2, 2026
Lipocine has updated the corporate presentation it uses in meetings with investors, analysts and other stakeholders. The refreshed materials have been formally filed and are now available as part of the company’s investor communications reso...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.